Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy

  • Gregory Q. Del PreteEmail author
  • Jeffrey D. LifsonEmail author
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 417)


Nonhuman primate (NHP) models of AIDS represent a potentially powerful component of the effort to understand in vivo sources of AIDS virus that persist in the setting of suppressive combination antiretroviral therapy (cART) and to develop and evaluate novel strategies for more definitive treatment of HIV infection (i.e., viral eradication “cure”, or sustained off-cART remission). Multiple different NHP models are available, each characterized by a particular NHP species, infecting virus, and cART regimen, and each with a distinct capacity to recapitulate different aspects of HIV infection. Given these different biological characteristics, and their associated strengths and limitations, different models may be preferred to address different questions pertaining to virus persistence and cure research, or to evaluate different candidate intervention approaches. Recent developments in improved cART regimens for use in NHPs, new viruses, a wider array of sensitive virologic assay approaches, and a better understanding of pathogenesis should allow even greater contributions from NHP models to this important area of HIV research in the future.


Financial Support

The authors were supported with federal funds from the National Cancer Institute, National Institutes of Health under contract HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.


  1. Al-Dakkak I, Patel S, McCann E, Gadkari A, Prajapati G, Maiese EM (2013) The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: a systematic review and meta-analysis. AIDS care 25(4):400–414. doi:10.1080/09540121.2012.712667CrossRefPubMedGoogle Scholar
  2. Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes SH, Kewalramani VN (2004) In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol 78(24):13553–13561CrossRefGoogle Scholar
  3. Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, Flanary L, Oswald K, Piatak M Jr, Smedley J, Shao W, Bischofberger N, Maldarelli F, Kimata JT, Mellors JW, Hu SL, Coffin JM, Lifson JD, KewalRamani VN (2007) Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol 81(22):12145–12155CrossRefGoogle Scholar
  4. Ananworanich J, Chomont N, Eller LA, Kroon E, Tovanabutra S, Bose M, Nau M, Fletcher JL, Tipsuk S, Vandergeeten C, O’Connell RJ, Pinyakorn S, Michael N, Phanuphak N, Robb ML, Rv, groups RSs (2016) HIV DNA set point is rapidly established in acute HIV infection and dramatically reduced by early ART. EBioMedicine 11:68–72. doi:10.1016/j.ebiom.2016.07.024CrossRefGoogle Scholar
  5. Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, Russell-Lodrigue K, Bohm RP, Cheng-Mayer C, Hong Z, Markowitz M, Ho DD (2014) Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science 343(6175):1151–1154. doi:10.1126/science.1248707CrossRefPubMedPubMedCentralGoogle Scholar
  6. Andrews CD, Yueh YL, Spreen WR, St Bernard L, Boente-Carrera M, Rodriguez K, Gettie A, Russell-Lodrigue K, Blanchard J, Ford S, Mohri H, Cheng-Mayer C, Hong Z, Ho DD, Markowitz M (2015) A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med 7(270):270ra274. doi:10.1126/scitranslmed.3010298CrossRefGoogle Scholar
  7. Andrews CD, Bernard LS, Poon AY, Mohri H, Gettie N, Spreen WR, Gettie A, Russell-Lodrigue K, Blanchard J, Hong Z, Ho DD, Markowitz M (2017) Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251. AIDS 31(4):461–467. doi:10.1097/QAD.0000000000001343CrossRefPubMedPubMedCentralGoogle Scholar
  8. Antiretroviral Therapy Cohort Collaboration (2017) Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. doi:10.1016/S2352-3018(17)30066-8CrossRefGoogle Scholar
  9. Arthur LO, Bess JW Jr, Urban RG, Strominger JL, Morton WR, Mann DL, Henderson LE, Benveniste RE (1995) Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol 69(5):3117–3124PubMedPubMedCentralGoogle Scholar
  10. Asmal M, Luedemann C, Lavine CL, Mach LV, Balachandran H, Brinkley C, Denny TN, Lewis MG, Anderson H, Pal R, Sok D, Le K, Pauthner M, Hahn BH, Shaw GM, Seaman MS, Letvin NL, Burton DR, Sodroski JG, Haynes BF, Santra S (2015) Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. Virology 475:37–45. doi:10.1016/j.virol.2014.10.032CrossRefPubMedGoogle Scholar
  11. Balzarini J, Weeger M, Camarasa MJ, De Clercq E, Uberla K (1995) Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem Biophys Res Commun 211(3):850–856CrossRefGoogle Scholar
  12. Balzarini J, De Clercq E, Uberla K (1997) SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1-specific reverse transcriptase inhibitors after passage in rhesus macaques. J Acquir Immune Defic Syndr Hum Retrovirol 15(1):1–4CrossRefGoogle Scholar
  13. Barouch DH, Ghneim K, Bosche WJ, Li Y, Berkemeier B, Hull M, Bhattacharyya S, Cameron M, Liu J, Smith K, Borducchi E, Cabral C, Peter L, Brinkman A, Shetty M, Li H, Gittens C, Baker C, Wagner W, Lewis MG, Colantonio A, Kang HJ, Li W, Lifson JD, Piatak M Jr, Sekaly RP (2016) Rapid inflammasome activation following mucosal siv infection of rhesus monkeys. Cell 165(3):656–667. doi:10.1016/j.cell.2016.03.021CrossRefPubMedPubMedCentralGoogle Scholar
  14. Baskin GB, Murphey-Corb M, Watson EA, Martin LN (1988) Necropsy findings in rhesus monkeys experimentally infected with cultured simian immunodeficiency virus (SIV)/delta. Vet Pathol 25(6):456–467. doi:10.1177/030098588802500609CrossRefPubMedGoogle Scholar
  15. Beliakova-Bethell N, Hezareh M, Wong JK, Strain MC, Lewinski MK, Richman DD, Spina CA (2017) Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. Virology 508:127–133. doi:10.1016/j.virol.2017.05.008CrossRefPubMedPubMedCentralGoogle Scholar
  16. Blakley GB, Beamer TW, Dukelow WR (1981) Characteristics of the menstrual cycle in nonhuman primates. IV. Timed mating in Macaca nemestrina. Lab Anim 15(4):351–353CrossRefGoogle Scholar
  17. Borsetti A, Baroncelli S, Maggiorella MT, Bellino S, Moretti S, Sernicola L, Belli R, Ridolfi B, Farcomeni S, Negri DR, Cafaro A, Ensoli B, Titti F (2008) Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Adv Virol 153(3):463–472. doi:10.1007/s00705-007-0009-2CrossRefGoogle Scholar
  18. Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V (2017) Benzotriazoles reactivate latent HIV-1 through inactivation of STAT5 SUMOylation. Cell Rep 18(5):1324–1334. doi:10.1016/j.celrep.2017.01.022CrossRefPubMedPubMedCentralGoogle Scholar
  19. Bourry O, Mannioui A, Sellier P, Roucairol C, Durand-Gasselin L, Dereuddre-Bosquet N, Benech H, Roques P, Le Grand R (2010) Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology 7:78. doi:10.1186/1742-4690-7-78CrossRefPubMedPubMedCentralGoogle Scholar
  20. Brandin E, Thorstensson R, Bonhoeffer S, Albert J (2006) Rapid viral decay in simian immunodeficiency virus-infected macaques receiving quadruple antiretroviral therapy. J Virol 80(19):9861–9864CrossRefGoogle Scholar
  21. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12(12):1365–1371. doi:10.1038/nm1511CrossRefPubMedGoogle Scholar
  22. Brenchley JM, Vinton C, Tabb B, Hao XP, Connick E, Paiardini M, Lifson JD, Silvestri G, Estes JD (2012) Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood 120(20):4172–4181CrossRefGoogle Scholar
  23. Brennan G, Kozyrev Y, Hu SL (2008) TRIMCyp expression in old world primates macaca nemestrina and macaca fascicularis. Proc Natl Acad Sci USA 105(9):3569–3574. doi:10.1073/pnas.0709511105CrossRefPubMedGoogle Scholar
  24. Bruner KM, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, Ho YC, Richman DD, Deeks SG, Siliciano JD, Siliciano RF (2016) Defective proviruses rapidly accumulate during acute HIV-1 infection. Nat Med 22(9):1043–1049. doi:10.1038/nm.4156CrossRefPubMedPubMedCentralGoogle Scholar
  25. Burdo TH, Marcondes MC, Lanigan CM, Penedo MC, Fox HS (2005) Susceptibility of Chinese rhesus monkeys to SIV infection. Aids 19(15):1704–1706CrossRefGoogle Scholar
  26. Burns DP, Collignon C, Desrosiers RC (1993) Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys. J Virol 67(7):4104–4113PubMedPubMedCentralGoogle Scholar
  27. Buzon MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, Gatell JM, Domingo P, Paredes R, Sharkey M, Palmer S, Stevenson M, Clotet B, Blanco J, Martinez-Picado J (2010) HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med 16(4):460–465. doi:10.1038/nm.2111CrossRefPubMedGoogle Scholar
  28. Cabrera C, Chang L, Stone M, Busch M, Wilson DH (2015) Rapid, fully automated digital immunoassay for p24 protein with the sensitivity of nucleic acid amplification for detecting acute HIV infection. Clin Chem 61(11):1372–1380. doi:10.1373/clinchem.2015.243287CrossRefPubMedGoogle Scholar
  29. Cain BT, Pham NH, Budde ML, Greene JM, Weinfurter JT, Scarlotta M, Harris M, Chin E, O’Connor SL, Friedrich TC, O’Connor DH (2013) T cell response specificity and magnitude against SIVmac239 are not concordant in major histocompatibility complex-matched animals. Retrovirology 10:116. doi:10.1186/1742-4690-10-116CrossRefPubMedPubMedCentralGoogle Scholar
  30. Cartwright EK, Spicer L, Smith SA, Lee D, Fast R, Paganini S, Lawson BO, Nega M, Easley K, Schmitz JE, Bosinger SE, Paiardini M, Chahroudi A, Vanderford TH, Estes JD, Lifson JD, Derdeyn CA, Silvestri G (2016) CD8(+) lymphocytes are required for maintaining viral suppression in siv-infected macaques treated with short-term antiretroviral therapy. Immunity 45(3):656–668. doi:10.1016/j.immuni.2016.08.018CrossRefPubMedPubMedCentralGoogle Scholar
  31. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, Kremer G, Nogueira L, Braunschweig M, Scheid JF, Horwitz JA, Shimeliovich I, Ben-Avraham S, Witmer-Pack M, Platten M, Lehmann C, Burke LA, Hawthorne T, Gorelick RJ, Walker BD, Keler T, Gulick RM, Fatkenheuer G, Schlesinger SJ, Nussenzweig MC (2015) Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522(7557):487–491. doi:10.1038/nature14411CrossRefPubMedPubMedCentralGoogle Scholar
  32. Cecchinato V, Tryniszewska E, Ma ZM, Vaccari M, Boasso A, Tsai WP, Petrovas C, Fuchs D, Heraud JM, Venzon D, Shearer GM, Koup RA, Lowy I, Miller CJ, Franchini G (2008) Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol 180(8):5439–5447CrossRefGoogle Scholar
  33. Chakrabarti L, Guyader M, Alizon M, Daniel MD, Desrosiers RC, Tiollais P, Sonigo P (1987) Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses. Nature 328(6130):543–547. doi:10.1038/328543a0CrossRefPubMedGoogle Scholar
  34. Chang HW, Tartaglia LJ, Whitney JB, Lim SY, Sanisetty S, Lavine CL, Seaman MS, Rademeyer C, Williamson C, Ellingson-Strouss K, Stamatatos L, Kublin J, Barouch DH (2015) Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks. J Virol 89(4):1965–1974. doi:10.1128/JVI.03279-14CrossRefPubMedGoogle Scholar
  35. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF (1997) Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387(6629):183–188CrossRefGoogle Scholar
  36. Cleary S, McIntyre D (2010) Financing equitable access to antiretroviral treatment in South Africa. BMC Health Serv Res 10(Suppl 1):S2. doi:10.1186/1472-6963-10-s1-s2CrossRefPubMedPubMedCentralGoogle Scholar
  37. Clements JE, Li M, Gama L, Bullock B, Carruth LM, Mankowski JL, Zink MC (2005) The central nervous system is a viral reservoir in simian immunodeficiency virus–infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol 11(2):180–189CrossRefGoogle Scholar
  38. Clements JE, Gama L, Graham DR, Mankowski JL, Zink MC (2011) A simian immunodeficiency virus macaque model of highly active antiretroviral treatment: viral latency in the periphery and the central nervous system. Curr Opin HIV AIDS 6(1):37–42CrossRefGoogle Scholar
  39. Cohn LB, Silva IT, Oliveira TY, Rosales RA, Parrish EH, Learn GH, Hahn BH, Czartoski JL, McElrath MJ, Lehmann C, Klein F, Caskey M, Walker BD, Siliciano JD, Siliciano RF, Jankovic M, Nussenzweig MC (2015) HIV-1 integration landscape during latent and active infection. Cell 160(3):420–432. doi:10.1016/j.cell.2015.01.020CrossRefPubMedPubMedCentralGoogle Scholar
  40. Crowell TA, Fletcher JL, Sereti I, Pinyakorn S, Dewar R, Krebs SJ, Chomchey N, Rerknimitr R, Schuetz A, Michael NL, Phanuphak N, Chomont N, Ananworanich J, Group RSS (2016) Initiation of antiretroviral therapy before detection of colonic infiltration by HIV reduces viral reservoirs, inflammation and immune activation. J Int AIDS Soc 19(1):21163. doi:10.7448/IAS.19.1.21163CrossRefGoogle Scholar
  41. Daniel MD, Letvin NL, King NW, Kannagi M, Sehgal PK, Hunt RD, Kanki PJ, Essex M, Desrosiers RC (1985) Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 228(4704):1201–1204CrossRefGoogle Scholar
  42. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC (1992) Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258(5090):1938–1941CrossRefGoogle Scholar
  43. de Groot NG, Heijmans CM, Koopman G, Verschoor EJ, Bogers WM, Bontrop RE (2011) TRIM5 allelic polymorphism in macaque species/populations of different geographic origins: its impact on SIV vaccine studies. Tissue Antigens 78(4):256–262. doi:10.1111/j.1399-0039.2011.01768.xCrossRefPubMedGoogle Scholar
  44. Deere JD, Higgins J, Cannavo E, Villalobos A, Adamson L, Fromentin E, Schinazi RF, Luciw PA, North TW (2010) Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. PLoS ONE 5(7):e11640CrossRefGoogle Scholar
  45. Deere JD, Kauffman RC, Cannavo E, Higgins J, Villalobos A, Adamson L, Schinazi RF, Luciw PA, North TW (2014) Analysis of multiply spliced transcripts in lymphoid tissue reservoirs of rhesus macaques infected with RT-SHIV during HAART. PLoS ONE 9(2):e87914. doi:10.1371/journal.pone.0087914CrossRefPubMedPubMedCentralGoogle Scholar
  46. Del Prete GQ, Ailers B, Moldt B, Keele BF, Estes JD, Rodriguez A, Sampias M, Oswald K, Fast R, Trubey CM, Chertova E, Smedley J, LaBranche CC, Montefiori DC, Burton DR, Shaw GM, Markowitz M, Piatak M Jr, KewalRamani VN, Bieniasz PD, Lifson JD, Hatziioannou T (2014a) Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. Cell Host Microbe 16(3):412–418. doi:10.1016/j.chom.2014.08.003CrossRefPubMedPubMedCentralGoogle Scholar
  47. Del Prete GQ, Shoemaker R, Oswald K, Lara A, Trubey CM, Fast R, Schneider DK, Kiser R, Coalter V, Wiles A, Wiles R, Freemire B, Keele BF, Estes JD, Quinones OA, Smedley J, Macallister R, Sanchez RI, Wai JS, Tan CM, Alvord WG, Hazuda DJ, Piatak M Jr, Lifson JD (2014b) Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in sivmac239-infected indian rhesus macaques. Antimicrob Agents Chemother 58(11):6790–6806. doi:10.1128/aac.03746-14CrossRefPubMedPubMedCentralGoogle Scholar
  48. Del Prete GQ, Oswald K, Lara A, Shoemaker R, Smedley J, Macallister R, Coalter V, Wiles A, Wiles R, Li Y, Fast R, Kiser R, Lu B, Zheng J, Alvord WG, Trubey CM, Piatak M Jr, Deleage C, Keele BF, Estes JD, Hesselgesser J, Geleziunas R, Lifson JD (2015) Elevated plasma viral loads in romidepsin-treated simian immunodeficiency virus-infected rhesus macaques on suppressive combination antiretroviral therapy. Antimicrob Agents Chemother 60(3):1560–1572. doi:10.1128/AAC.02625-15CrossRefPubMedGoogle Scholar
  49. Del Prete GQ, Lifson JD, Keele BF (2016a) Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences. Curr Opin HIV AIDS 11(6):546–554. doi:10.1097/COH.0000000000000311CrossRefPubMedPubMedCentralGoogle Scholar
  50. Del Prete GQ, Smedley J, Macallister R, Jones GS, Li B, Hattersley J, Zheng J, Piatak M Jr, Keele BF, Hesselgesser J, Geleziunas R, Lifson JD (2016b) Short communication: comparative evaluation of coformulated injectable combination antiretroviral therapy regimens in simian immunodeficiency virus-infected rhesus macaques. AIDS Res Hum Retroviruses 32(2):163–168. doi:10.1089/AID.2015.0130CrossRefPubMedPubMedCentralGoogle Scholar
  51. Deleage C, Wietgrefe SW, Del Prete G, Morcock DR, Hao XP, Piatak M Jr, Bess J, Anderson JL, Perkey KE, Reilly C, McCune JM, Haase AT, Lifson JD, Schacker TW, Estes JD (2016) Defining HIV and SIV reservoirs in lymphoid tissues. Pathog Immun 1(1):68–106CrossRefGoogle Scholar
  52. Deng K, Zink MC, Clements JE, Siliciano RF (2012) A quantitative measurement of antiviral activity of anti-human immunodeficiency virus type 1 drugs against simian immunodeficiency virus infection: dose-response curve slope strongly influences class-specific inhibitory potential. J Virol 86(20):11368–11372CrossRefGoogle Scholar
  53. Desrosiers RC, Wyand MS, Kodama T, Ringler DJ, Arthur LO, Sehgal PK, Letvin NL, King NW, Daniel MD (1989) Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci USA 86(16):6353–6357CrossRefGoogle Scholar
  54. Dinoso JB, Rabi SA, Blankson JN, Gama L, Mankowski JL, Siliciano RF, Zink MC, Clements JE (2009) A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol 83(18):9247–9257CrossRefGoogle Scholar
  55. Dobard CW, Taylor A, Sharma S, Anderson PL, Bushman LR, Chuong D, Pau CP, Hanson D, Wang L, Garcia-Lerma JG, McGowan I, Rohan L, Heneine W (2015) Protection against rectal chimeric simian/human immunodeficiency virus transmission in macaques by rectal-specific gel formulations of maraviroc and tenofovir. J Infect Dis 212(12):1988–1995. doi:10.1093/infdis/jiv334CrossRefPubMedPubMedCentralGoogle Scholar
  56. Donahue RE, Metzger ME, Bonifacino AC, Parker DM, Leitman SF, Cullis H, Lienesch M (2014) Optimization of the spectra optia for leukapheresis of very small subjects. Blood 124:3857–3857Google Scholar
  57. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, Ingerman MJ, Witek J, Kedanis RJ, Natkin J, DeSimone J, Pomerantz RJ (1999) Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282(17):1627–1632CrossRefGoogle Scholar
  58. Dunham RM, Gordon SN, Vaccari M, Piatak M, Huang Y, Deeks SG, Lifson J, Franchini G, McCune JM (2012) Preclinical evaluation of HIV eradication strategies in the simian immunodeficiency virus-infected rhesus macaque: a pilot study testing inhibition of indoleamine 2,3-Dioxygenase. AIDS Res Hum RetrovirusesGoogle Scholar
  59. Durand CM, Blankson JN, Siliciano RF (2012) Developing strategies for HIV-1 eradication. Trends Immunol 33(11):554–562CrossRefGoogle Scholar
  60. Elliott JH, McMahon JH, Chang CC, Lee SA, Hartogensis W, Bumpus N, Savic R, Roney J, Hoh R, Solomon A, Piatak M, Gorelick RJ, Lifson J, Bacchetti P, Deeks SG, Lewin SR (2015) Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2(12):e520–e529. doi:10.1016/S2352-3018(15)00226-XCrossRefPubMedPubMedCentralGoogle Scholar
  61. Estes JD, Gordon SN, Zeng M, Chahroudi AM, Dunham RM, Staprans SI, Reilly CS, Silvestri G, Haase AT (2008) Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J Immunol 180(10):6798–6807CrossRefGoogle Scholar
  62. Estes JD, Harris LD, Klatt NR, Tabb B, Pittaluga S, Paiardini M, Barclay GR, Smedley J, Pung R, Oliveira KM, Hirsch VM, Silvestri G, Douek DC, Miller CJ, Haase AT, Lifson J, Brenchley JM (2010) Damaged intestinal epithelial integrity linked to microbial translocation in pathogenic simian immunodeficiency virus infections. PLoS Pathog 6(8):e1001052. doi:10.1371/journal.ppat.1001052CrossRefPubMedPubMedCentralGoogle Scholar
  63. European Collaborative S, Patel D, Cortina-Borja M, Thorne C, Newell ML (2007) Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis: Off Publ Infect Dis Soc Am 44(12):1647–1656. doi:10.1086/518284CrossRefGoogle Scholar
  64. Fennessey CM, Pinkevych M, Immonen TT, Reynaldi A, Venturi V, Nadella P, Reid C, Newman L, Lipkey L, Oswald K, Bosche WJ, Trivett MT, Ohlen C, Ott DE, Estes JD, Del Prete GQ, Lifson JD, Davenport MP, Keele BF (2017) Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy. PLoS Pathog 13(5):e1006359. doi:10.1371/journal.ppat.1006359CrossRefPubMedPubMedCentralGoogle Scholar
  65. Fischer M, Gunthard HF, Opravil M, Joos B, Huber W, Bisset LR, Ott P, Boni J, Weber R, Cone RW (2000) Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy. AIDS Res Hum Retroviruses 16(12):1135–1140CrossRefGoogle Scholar
  66. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW (2014) Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci USA 111(6):2307–2312. doi:10.1073/pnas.1318249111CrossRefPubMedGoogle Scholar
  67. Frange P, Faye A, Avettand-Fenoel V, Bellaton E, Descamps D, Angin M, David A, Caillat-Zucman S, Peytavin G, Dollfus C, Le Chenadec J, Warszawski J, Rouzioux C, Saez-Cirion A, Cohort AE-CP, the AEPVsg (2016) HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report. Lancet HIV 3(1):e49–e54. doi:10.1016/S2352-3018(15)00232-5CrossRefGoogle Scholar
  68. Fukazawa Y, Lum R, Okoye AA, Park H, Matsuda K, Bae JY, Hagen SI, Shoemaker R, Deleage C, Lucero C, Morcock D, Swanson T, Legasse AW, Axthelm MK, Hesselgesser J, Geleziunas R, Hirsch VM, Edlefsen PT, Piatak M Jr, Estes JD, Lifson JD, Picker LJ (2015) B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med 21(2):132–139. doi:10.1038/nm.3781CrossRefPubMedPubMedCentralGoogle Scholar
  69. Fultz PN, McClure HM, Anderson DC, Swenson RB, Anand R, Srinivasan A (1986) Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys). Proc Natl Acad Sci USA 83(14):5286–5290CrossRefGoogle Scholar
  70. Fultz PN, McClure HM, Swenson RB, Anderson DC (1989) HIV infection of chimpanzees as a model for testing chemotherapeutics. Intervirology 30(suppl 1):51–58CrossRefGoogle Scholar
  71. Gama L, Abreu CM, Shirk EN, Price SL, Li M, Laird GM, Pate KA, Wietgrefe SW, O’Connor SL, Pianowski L, Haase AT, Van Lint C, Siliciano RF, Clements JE, Group L-SS (2017) Reactivation of simian immunodeficiency virus reservoirs in the brain of virally suppressed macaques. AIDS 31(1):5–14. doi:10.1097/QAD.0000000000001267CrossRefGoogle Scholar
  72. Garcia JV (2016) In vivo platforms for analysis of HIV persistence and eradication. J Clin Investig 126(2):424–431. doi:10.1172/JCI80562CrossRefPubMedGoogle Scholar
  73. Gardner M (2016) A historical perspective: simian AIDS-an accidental windfall. J Med Primatol 45(5):212–214. doi:10.1111/jmp.12234CrossRefPubMedGoogle Scholar
  74. Graham DR, Gama L, Queen SE, Li M, Brice AK, Kelly KM, Mankowski JL, Clements JE, Zink MC (2011) Initiation of HAART during acute simian immunodeficiency virus infection rapidly controls virus replication in the CNS by enhancing immune activity and preserving protective immune responses. J Neurovirol 17(1):120–130CrossRefGoogle Scholar
  75. Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, Pedersen C, Okulicz JF, McClure M, Babiker A, Weber J, Fidler S (2012) Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS ONE 7(8):e43754CrossRefGoogle Scholar
  76. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M Jr, Lifson JD, Picker LJ (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473(7348):523–527CrossRefGoogle Scholar
  77. Hansen SG, Piatak M Jr, Ventura AB, Hughes CM, Gilbride RM, Ford JC, Oswald K, Shoemaker R, Li Y, Lewis MS, Gilliam AN, Xu G, Whizin N, Burwitz BJ, Planer SL, Turner JM, Legasse AW, Axthelm MK, Nelson JA, Fruh K, Sacha JB, Estes JD, Keele BF, Edlefsen PT, Lifson JD, Picker LJ (2013) Immune clearance of highly pathogenic SIV infection. Nature 502(7469):100–104. doi:10.1038/nature12519CrossRefPubMedPubMedCentralGoogle Scholar
  78. Hassounah SA, Mesplede T, Quashie PK, Oliveira M, Sandstrom PA, Wainberg MA (2014) Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors. J Virol 88(17):9683–9692. doi:10.1128/jvi.00947-14CrossRefPubMedPubMedCentralGoogle Scholar
  79. Hatziioannou T, Bieniasz PD (2011) Antiretroviral restriction factors. Curr Opin Virol 1(6):526–532. doi:10.1016/j.coviro.2011.10.007CrossRefPubMedPubMedCentralGoogle Scholar
  80. Hatziioannou T, Cowan S, Von Schwedler UK, Sundquist WI, Bieniasz PD (2004) Species-specific tropism determinants in the human immunodeficiency virus type 1 capsid. J Virol 78(11):6005–6012. doi:10.1128/JVI.78.11.6005-6012.2004CrossRefPubMedPubMedCentralGoogle Scholar
  81. Hatziioannou T, Ambrose Z, Chung NP, Piatak M Jr, Yuan F, Trubey CM, Coalter V, Kiser R, Schneider D, Smedley J, Pung R, Gathuka M, Estes JD, Veazey RS, KewalRamani VN, Lifson JD, Bieniasz PD (2009) A macaque model of HIV-1 infection. Proc Natl Acad Sci USA 106(11):4425–4429CrossRefGoogle Scholar
  82. Hatziioannou T, Del Prete GQ, Keele BF, Estes JD, McNatt MW, Bitzegeio J, Raymond A, Rodriguez A, Schmidt F, Mac Trubey C, Smedley J, Piatak M Jr, KewalRamani VN, Lifson JD, Bieniasz PD (2014) HIV-1-induced AIDS in monkeys. Science 344(6190):1401–1405. doi:10.1126/science.1250761CrossRefPubMedPubMedCentralGoogle Scholar
  83. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, Vacca JP, Handt L, Motzel SL, Klein HJ, Dornadula G, Danovich RM, Witmer MV, Wilson KA, Tussey L, Schleif WA, Gabryelski LS, Jin L, Miller MD, Casimiro DR, Emini EA, Shiver JW (2004) Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 305(5683):528–532CrossRefGoogle Scholar
  84. Hill AL, Rosenbloom DI, Fu F, Nowak MA, Siliciano RF (2014) Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci USA 111(37):13475–13480. doi:10.1073/pnas.1406663111CrossRefPubMedGoogle Scholar
  85. Hill AL, Rosenbloom DI, Goldstein E, Hanhauser E, Kuritzkes DR, Siliciano RF, Henrich TJ (2016) Real-time predictions of reservoir size and rebound time during antiretroviral therapy interruption trials for HIV. PLoS Pathog 12(4):e1005535. doi:10.1371/journal.ppat.1005535CrossRefPubMedPubMedCentralGoogle Scholar
  86. Hirsch VM, Johnson PR (1994) Pathogenic diversity of simian immunodeficiency viruses. Virus Res 32(2):183–203CrossRefGoogle Scholar
  87. Hirsch VM, Lifson JD (2000) Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. Adv Pharmacol 49:437–477CrossRefGoogle Scholar
  88. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR (1989) An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 339(6223):389–392. doi:10.1038/339389a0CrossRefPubMedGoogle Scholar
  89. Hirsch V, Adger-Johnson D, Campbell B, Goldstein S, Brown C, Elkins WR, Montefiori DC (1997) A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol 71(2):1608–1620PubMedPubMedCentralGoogle Scholar
  90. Hofman MJ, Higgins J, Matthews TB, Pedersen NC, Tan C, Schinazi RF, North TW (2004) Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. Antimicrob Agents Chemother 48(9):3483–3490CrossRefGoogle Scholar
  91. Hryniewicz A, Boasso A, Edghill-Smith Y, Vaccari M, Fuchs D, Venzon D, Nacsa J, Betts MR, Tsai WP, Heraud JM, Beer B, Blanset D, Chougnet C, Lowy I, Shearer GM, Franchini G (2006) CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 108(12):3834–3842CrossRefGoogle Scholar
  92. Hunt PW (2012) HIV and inflammation: mechanisms and consequences. Curr HIV/AIDS Rep 9(2):139–147. doi:10.1007/s11904-012-0118-8CrossRefPubMedGoogle Scholar
  93. Ikeda Y, Ylinen LM, Kahar-Bador M, Towers GJ (2004) Influence of gag on human immunodeficiency virus type 1 species-specific tropism. J Virol 78(21):11816–11822. doi:10.1128/JVI.78.21.11816-11822.2004CrossRefPubMedPubMedCentralGoogle Scholar
  94. Jasny E, Geer S, Frank I, Vagenas P, Aravantinou M, Salazar AM, Lifson JD, Piatak M Jr, Gettie A, Blanchard JL, Robbiani M (2012) Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy. J Acquir Immune Defic Syndr 61(4):425–435CrossRefGoogle Scholar
  95. Joag SV, Stephens EB, Adams RJ, Foresman L, Narayan O (1994) Pathogenesis of SIVmac infection in Chinese and Indian rhesus macaques: effects of splenectomy on virus burden. Virology 200(2):436–446. doi:10.1006/viro.1994.1207CrossRefPubMedGoogle Scholar
  96. Kaizu M, Ami Y, Nakasone T, Sasaki Y, Izumi Y, Sato H, Takahashi E, Sakai K, Shinohara K, Nakanishi K, Honda M (2003) Higher levels of IL-18 circulate during primary infection of monkeys with a pathogenic SHIV than with a nonpathogenic SHIV. Virology 313(1):8–12CrossRefGoogle Scholar
  97. Kanki PJ, McLane MF, King NW Jr, Letvin NL, Hunt RD, Sehgal P, Daniel MD, Desrosiers RC, Essex M (1985) Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III. Science 228(4704):1199–1201CrossRefGoogle Scholar
  98. Kearney MF, Wiegand A, Shao W, Coffin JM, Mellors JW, Lederman M, Gandhi RT, Keele BF, Li JZ (2015) Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping of antiretroviral therapy. J Virol 90(3):1369–1376. doi:10.1128/JVI.02139-15CrossRefPubMedGoogle Scholar
  99. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, Bibollet-Ruche F, Chen Y, Wain LV, Liegeois F, Loul S, Ngole EM, Bienvenue Y, Delaporte E, Brookfield JF, Sharp PM, Shaw GM, Peeters M, Hahn BH (2006) Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 313(5786):523–526. doi:10.1126/science.1126531CrossRefPubMedPubMedCentralGoogle Scholar
  100. Keele BF, Jones JH, Terio KA, Estes JD, Rudicell RS, Wilson ML, Li Y, Learn GH, Beasley TM, Schumacher-Stankey J, Wroblewski E, Mosser A, Raphael J, Kamenya S, Lonsdorf EV, Travis DA, Mlengeya T, Kinsel MJ, Else JG, Silvestri G, Goodall J, Sharp PM, Shaw GM, Pusey AE, Hahn BH (2009) Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 460(7254):515–519. doi:10.1038/nature08200CrossRefPubMedPubMedCentralGoogle Scholar
  101. Kersh EN, Henning T, Vishwanathan SA, Morris M, Butler K, Adams DR, Guenthner P, Srinivasan P, Smith J, Radzio J, Garcia-Lerma JG, Dobard C, Heneine W, McNicholl J (2014) SHIV susceptibility changes during the menstrual cycle of pigtail macaques. J Med Primatol 43(5):310–316. doi:10.1111/jmp.12124CrossRefPubMedPubMedCentralGoogle Scholar
  102. Kersh EN, Henning TR, Dobard C, Heneine W, McNicholl JM (2015a) Short communication: practical experience with analysis and design of repeat low-dose SHIVSF162P3 exposure studies in female pigtail macaques with varying susceptibility during menstrual cycling. AIDS Res Hum Retroviruses 31(11):1166–1169. doi:10.1089/AID.2014.0373CrossRefPubMedPubMedCentralGoogle Scholar
  103. Kersh EN, Ritter J, Butler K, Ostergaard SD, Hanson D, Ellis S, Zaki S, McNicholl JM (2015b) Relationship of estimated SHIV acquisition time points during the menstrual cycle and thinning of vaginal epithelial layers in pigtail macaques. Sex Transm Dis 42(12):694–701. doi:10.1097/OLQ.0000000000000367CrossRefPubMedPubMedCentralGoogle Scholar
  104. Kirmaier A, Wu F, Newman RM, Hall LR, Morgan JS, O’Connor S, Marx PA, Meythaler M, Goldstein S, Buckler-White A, Kaur A, Hirsch VM, Johnson WE (2010) TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species. PLoS Biol 8(8). doi:10.1371/journal.pbio.1000462CrossRefGoogle Scholar
  105. Klatt NR, Harris LD, Vinton CL, Sung H, Briant JA, Tabb B, Morcock D, McGinty JW, Lifson JD, Lafont BA, Martin MA, Levine AD, Estes JD, Brenchley JM (2010) Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol 3(4):387–398. doi:10.1038/mi.2010.14CrossRefPubMedPubMedCentralGoogle Scholar
  106. Klatt NR, Canary LA, Vanderford TH, Vinton CL, Engram JC, Dunham RM, Cronise HE, Swerczek JM, Lafont BA, Picker LJ, Silvestri G, Brenchley JM (2012) Dynamics of simian immunodeficiency virus SIVmac239 infection in pigtail macaques. J Virol 86(2):1203–1213. doi:10.1128/JVI.06033-11CrossRefPubMedPubMedCentralGoogle Scholar
  107. Krebs KC, Jin Z, Rudersdorf R, Hughes AL, O’Connor DH (2005) Unusually high frequency MHC class I alleles in Mauritian origin cynomolgus macaques. J Immunol 175(8):5230–5239CrossRefGoogle Scholar
  108. Lee FH, Mason R, Welles H, Learn GH, Keele BF, Roederer M, Bar KJ (2015) Breakthrough virus neutralization resistance as a correlate of protection in a nonhuman primate heterologous simian immunodeficiency virus vaccine challenge study. J Virol 89(24):12388–12400. doi:10.1128/JVI.01531-15CrossRefPubMedPubMedCentralGoogle Scholar
  109. Letvin NL, Daniel MD, Sehgal PK, Desrosiers RC, Hunt RD, Waldron LM, MacKey JJ, Schmidt DK, Chalifoux LV, King NW (1985) Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 230(4721):71–73CrossRefGoogle Scholar
  110. Letvin NL, Rao SS, Montefiori DC, Seaman MS, Sun Y, Lim SY, Yeh WW, Asmal M, Gelman RS, Shen L, Whitney JB, Seoighe C, Lacerda M, Keating S, Norris PJ, Hudgens MG, Gilbert PB, Buzby AP, Mach LV, Zhang J, Balachandran H, Shaw GM, Schmidt SD, Todd JP, Dodson A, Mascola JR, Nabel GJ (2011) Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 3(81):81ra36. doi:10.1126/scitranslmed.3002351CrossRefGoogle Scholar
  111. Lewis MG, Norelli S, Collins M, Barreca ML, Iraci N, Chirullo B, Yalley-Ogunro J, Greenhouse J, Titti F, Garaci E, Savarino A (2010) Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology 7:21CrossRefGoogle Scholar
  112. Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, Kim E, Learn GH, Hahn P, Policicchio B, Brocca-Cofano E, Deleage C, Hao X, Chuang GY, Gorman J, Gardner M, Lewis MG, Hatziioannou T, Santra S, Apetrei C, Pandrea I, Alam SM, Liao HX, Shen X, Tomaras GD, Farzan M, Chertova E, Keele BF, Estes JD, Lifson JD, Doms RW, Montefiori DC, Haynes BF, Sodroski JG, Kwong PD, Hahn BH, Shaw GM (2016) Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci USA 113(24):E3413–E3422. doi:10.1073/pnas.1606636113CrossRefPubMedGoogle Scholar
  113. Liao CH, Kuang YQ, Liu HL, Zheng YT, Su B (2007) A novel fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection. AIDS 21(Suppl 8):S19–S26. doi:10.1097/01.aids.0000304692.09143.1bCrossRefPubMedGoogle Scholar
  114. Ling B, Veazey RS, Luckay A, Penedo C, Xu K, Lifson JD, Marx PA (2002) SIV(mac) pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. Aids 16(11):1489–1496CrossRefGoogle Scholar
  115. Ling B, Piatak M Jr, Rogers L, Johnson AM, Russell-Lodrigue K, Hazuda DJ, Lifson JD, Veazey RS (2014) Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques. PLoS ONE 9(7):e102795. doi:10.1371/journal.pone.0102795CrossRefPubMedPubMedCentralGoogle Scholar
  116. Liu J, Ghneim K, Sok D, Bosche WJ, Li Y, Chipriano E, Berkemeier B, Oswald K, Borducchi E, Cabral C, Peter L, Brinkman A, Shetty M, Jimenez J, Mondesir J, Lee B, Giglio P, Chandrashekar A, Abbink P, Colantonio A, Gittens C, Baker C, Wagner W, Lewis MG, Li W, Sekaly RP, Lifson JD, Burton DR, Barouch DH (2016) Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353(6303):1045–1049. doi:10.1126/science.aag0491CrossRefPubMedPubMedCentralGoogle Scholar
  117. Lopker M, Easlick J, Sterrett S, Decker JM, Barbian H, Learn G, Keele BF, Robinson JE, Li H, Hahn BH, Shaw GM, Bar KJ (2013) Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock. J Virol 87(10):5477–5492. doi:10.1128/JVI.03419-12CrossRefPubMedPubMedCentralGoogle Scholar
  118. Lowenstine LJ, Pedersen NC, Higgins J, Pallis KC, Uyeda A, Marx P, Lerche NW, Munn RJ, Gardner MB (1986) Seroepidemiologic survey of captive Old-World primates for antibodies to human and simian retroviruses, and isolation of a lentivirus from sooty mangabeys (Cercocebus atys). Int J Cancer 38(4):563–574CrossRefGoogle Scholar
  119. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, Enama ME, Plummer S, Holman L, Hendel CS, Gordon I, Casazza J, Conan-Cibotti M, Migueles SA, Tressler R, Bailer RT, McDermott A, Narpala S, O’Dell S, Wolf G, Lifson JD, Freemire BA, Gorelick RJ, Pandey JP, Mohan S, Chomont N, Fromentin R, Chun TW, Fauci AS, Schwartz RM, Koup RA, Douek DC, Hu Z, Capparelli E, Graham BS, Mascola JR, Ledgerwood JE, Team VRCS (2015) Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Transl Med 7(319):319ra206. doi:10.1126/scitranslmed.aad5752CrossRefGoogle Scholar
  120. Ma D, Xu C, Cillo AR, Policicchio B, Kristoff J, Haret-Richter G, Mellors JW, Pandrea I, Apetrei C (2015) Simian immunodeficiency virus SIVsab infection of rhesus macaques as a model of complete immunological suppression with persistent reservoirs of replication-competent virus: implications for cure research. J Virol 89(11):6155–6160. doi:10.1128/JVI.00256-15CrossRefPubMedPubMedCentralGoogle Scholar
  121. Malcolm RK, Veazey RS, Geer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJ, Doyle LA, Rasmussen KK, Goldman L, Ketas TJ, Moore JP (2012) Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 56(5):2251–2258. doi:10.1128/AAC.05810-11CrossRefPubMedPubMedCentralGoogle Scholar
  122. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW (2007) ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog 3(4):e46CrossRefGoogle Scholar
  123. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, Spindler J, Ferris AL, Mellors JW, Kearney MF, Coffin JM, Hughes SH (2014) HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345(6193):179–183. doi:10.1126/science.1254194CrossRefGoogle Scholar
  124. Manrique J, Piatak M, Lauer W, Johnson W, Mansfield K, Lifson J, Desrosiers R (2013) Influence of mismatch of Env sequences on vaccine protection by live attenuated simian immunodeficiency virus. J Virol 87(13):7246–7254. doi:10.1128/JVI.00798-13CrossRefPubMedPubMedCentralGoogle Scholar
  125. Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B, Zhong L, Wulfsohn M, Miller MD, Lee WA (2014) Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother 69(5):1362–1369. doi:10.1093/jac/dkt532CrossRefPubMedGoogle Scholar
  126. Marthas ML, Lu D, Penedo MC, Hendrickx AG, Miller CJ (2001) Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses. AIDS Res Hum Retroviruses 17(15):1455–1466. doi:10.1089/088922201753197123CrossRefPubMedPubMedCentralGoogle Scholar
  127. Marx PA, Li Y, Lerche NW, Sutjipto S, Gettie A, Yee JA, Brotman BH, Prince AM, Hanson A, Webster RG et al (1991) Isolation of a simian immunodeficiency virus related to human immunodeficiency virus type 2 from a west African pet sooty mangabey. J Virol 65(8):4480–4485PubMedPubMedCentralGoogle Scholar
  128. Mason RD, Welles HC, Adams C, Chakrabarti BK, Gorman J, Zhou T, Nguyen R, O’Dell S, Lusvarghi S, Bewley CA, Li H, Shaw GM, Sheng Z, Shapiro L, Wyatt R, Kwong PD, Mascola JR, Roederer M (2016) Targeted isolation of antibodies directed against major sites of SIV env vulnerability. PLoS Pathog 12(4):e1005537. doi:10.1371/journal.ppat.1005537CrossRefPubMedPubMedCentralGoogle Scholar
  129. Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG (2002) Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 16(1):53–61CrossRefGoogle Scholar
  130. McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJ, Bieniasz PD (2009) Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog 5(2):e1000300. doi:10.1371/journal.ppat.1000300CrossRefPubMedPubMedCentralGoogle Scholar
  131. Means RE, Greenough T, Desrosiers RC (1997) Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J Virol 71(10):7895–7902PubMedPubMedCentralGoogle Scholar
  132. Mee ET, Badhan A, Karl JA, Wiseman RW, Cutler K, Knapp LA, Almond N, O’Connor DH, Rose NJ (2009) MHC haplotype frequencies in a UK breeding colony of Mauritian cynomolgus macaques mirror those found in a distinct population from the same geographic origin. J Med Primatol 38(1):1–14. doi:10.1111/j.1600-0684.2008.00299.xCrossRefPubMedGoogle Scholar
  133. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgrefe S, La Franco-Scheuch L, Compton L, Duan L, Shore MD, Zupancic M, Busch M, Carlis J, Wolinsky S, Haase AT (2005) Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 79(14):9217–9227. doi:10.1128/JVI.79.14.9217-9227.2005CrossRefPubMedPubMedCentralGoogle Scholar
  134. Mohns MS, Greene JM, Cain BT, Pham NH, Gostick E, Price DA, O’Connor DH (2015) Expansion of simian immunodeficiency virus (SIV)-specific CD8 T cell lines from SIV-naive Mauritian cynomolgus macaques for adoptive transfer. J Virol 89(19):9748–9757. doi:10.1128/JVI.00993-15CrossRefPubMedPubMedCentralGoogle Scholar
  135. Moreau M, Le Tortorec A, Deleage C, Brown C, Denis H, Satie AP, Bourry O, Deureuddre-Bosquet N, Roques P, Le Grand R, Dejucq-Rainsford N (2012) Impact of short-term HAART initiated during the chronic stage or shortly post-exposure on SIV infection of male genital organs. PLoS ONE 7(5):e37348CrossRefGoogle Scholar
  136. Murphey-Corb M, Martin LN, Rangan SR, Baskin GB, Gormus BJ, Wolf RH, Andes WA, West M, Montelaro RC (1986) Isolation of an HTLV-III-related retrovirus from macaques with simian AIDS and its possible origin in asymptomatic mangabeys. Nature 321(6068):435–437. doi:10.1038/321435a0CrossRefPubMedGoogle Scholar
  137. Murphey-Corb M, Rajakumar P, Michael H, Nyaundi J, Didier PJ, Reeve AB, Mitsuya H, Sarafianos SG, Parniak MA (2012) Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine in vitro and in vivo. Antimicrob Agents Chemother 56(9):4707–4712. doi:10.1128/AAC.00723-12CrossRefPubMedPubMedCentralGoogle Scholar
  138. Murry JP, Higgins J, Matthews TB, Huang VY, Van Rompay KK, Pedersen NC, North TW (2003) Reversion of the M184 V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. J Virol 77(2):1120–1130CrossRefGoogle Scholar
  139. Naidu YM, Kestler HW 3rd, Li Y, Butler CV, Silva DP, Schmidt DK, Troup CD, Sehgal PK, Sonigo P, Daniel MD, Desrosiers RC (1988) Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J Virol 62(12):4691–4696PubMedPubMedCentralGoogle Scholar
  140. Neil SJ, Zang T, Bieniasz PD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451(7177):425–430. doi:10.1038/nature06553CrossRefPubMedGoogle Scholar
  141. Newman RM, Hall L, Kirmaier A, Pozzi LA, Pery E, Farzan M, O’Neil SP, Johnson W (2008) Evolution of a TRIM5-CypA splice isoform in old world monkeys. PLoS Pathog 4(2):e1000003. doi:10.1371/journal.ppat.1000003CrossRefPubMedPubMedCentralGoogle Scholar
  142. Nishimura Y, Shingai M, Willey R, Sadjadpour R, Lee WR, Brown CR, Brenchley JM, Buckler-White A, Petros R, Eckhaus M, Hoffman V, Igarashi T, Martin MA (2010) Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol 84(9):4769–4781. doi:10.1128/JVI.02279-09CrossRefPubMedPubMedCentralGoogle Scholar
  143. North TW, Van Rompay KK, Higgins J, Matthews TB, Wadford DA, Pedersen NC, Schinazi RF (2005) Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol 79(12):7349–7354CrossRefGoogle Scholar
  144. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, Adamson L, Shacklett BL, Schinazi RF, Luciw PA (2010) Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 84(6):2913–2922CrossRefGoogle Scholar
  145. Novembre FJ, Saucier M, Anderson DC, Klumpp SA, O’Neil SP, Brown CR 2nd, Hart CE, Guenthner PC, Swenson RB, McClure HM (1997) Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1. J Virol 71(5):4086–4091PubMedPubMedCentralGoogle Scholar
  146. O’Connor SL, Blasky AJ, Pendley CJ, Becker EA, Wiseman RW, Karl JA, Hughes AL, O’Connor DH (2007) Comprehensive characterization of MHC class II haplotypes in Mauritian cynomolgus macaques. Immunogenetics 59(6):449–462. doi:10.1007/s00251-007-0209-7CrossRefPubMedPubMedCentralGoogle Scholar
  147. Ohta Y, Masuda T, Tsujimoto H, Ishikawa K, Kodama T, Morikawa S, Nakai M, Honjo S, Hayami M (1988) Isolation of simian immunodeficiency virus from African green monkeys and seroepidemiologic survey of the virus in various non-human primates. Int J Cancer 41(1):115–122CrossRefGoogle Scholar
  148. O’Neil SP, Novembre FJ, Hill AB, Suwyn C, Hart CE, Evans-Strickfaden T, Anderson DC, deRosayro J, Herndon JG, Saucier M, McClure HM (2000) Progressive infection in a subset of HIV-1-positive chimpanzees. J Infect Dis 182(4):1051–1062. doi:10.1086/315823CrossRefPubMedGoogle Scholar
  149. Owens CM, Yang PC, Gottlinger H, Sodroski J (2003) Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. J Virol 77(1):726–731CrossRefGoogle Scholar
  150. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM (2003) New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 41(10):4531–4536CrossRefGoogle Scholar
  151. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105(10):3879–3884CrossRefGoogle Scholar
  152. Pandrea I, Gaufin T, Gautam R, Kristoff J, Mandell D, Montefiori D, Keele BF, Ribeiro RM, Veazey RS, Apetrei C (2011) Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion. PLoS Pathog 7(8):e1002170CrossRefGoogle Scholar
  153. Passaes CP, Bruel T, Decalf J, David A, Angin M, Monceaux V, Muller-Trutwin M, Noel N, Bourdic K, Lambotte O, Albert ML, Duffy D, Schwartz O, Saez-Cirion A, Consortium AR (2017) Ultrasensitive HIV-1 p 24 assay detects single infected cells and differences in reservoir induction by latency reversal agents. J Virol 91(6). doi:10.1128/JVI.02296-16
  154. Pathiraja V, Matar AJ, Gusha A, Huang CA, Duran-Struuck R (2013) Leukapheresis protocol for nonhuman primates weighing less than 10 kg. J Am Assoc Lab Anim Sci 52(1):70–77PubMedPubMedCentralGoogle Scholar
  155. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B, Swiss HIVCS, Frakfurt HIVCC, Euro SSG (2001) HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 286(20):2560–2567CrossRefGoogle Scholar
  156. Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, Sogaard OS, Rasmussen TA, Kent SJ, Kelleher AD, Davenport MP (2015) HIV reactivation from latency after treatment interruption occurs on average every 5–8 days-implications for HIV remission. PLoS Pathog 11(7):e1005000. doi:10.1371/journal.ppat.1005000CrossRefPubMedPubMedCentralGoogle Scholar
  157. Policicchio BB, Xu C, Brocca-Cofano E, Raehtz KD, He T, Ma D, Li H, Sivanandham R, Haret-Richter GS, Dunsmore T, Trichel A, Mellors JW, Hahn BH, Shaw GM, Ribeiro RM, Pandrea I, Apetrei C (2016) Multi-dose romidepsin reactivates replication competent SIV in post-antiretroviral rhesus macaque controllers. PLoS Pathog 12(9):e1005879. doi:10.1371/journal.ppat.1005879CrossRefPubMedPubMedCentralGoogle Scholar
  158. Post FA, Yazdanpanah Y, Schembri G, Lazzarin A, Reynes J, Maggiolo F, Yan M, Abram ME, Tran-Muchowski C, Cheng A, Rhee MS (2017) Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial. HIV Clin Trials:1–6. doi:10.1080/15284336.2017.1291867CrossRefGoogle Scholar
  159. Queen SE, Mears BM, Kelly KM, Dorsey JL, Liao Z, Dinoso JB, Gama L, Adams RJ, Zink MC, Clements JE, Kent SJ, Mankowski JL (2011) Replication-competent simian immunodeficiency virus (SIV) Gag escape mutations archived in latent reservoirs during antiretroviral treatment of SIV-infected macaques. J Virol 85(17):9167–9175CrossRefGoogle Scholar
  160. Radzio J, Aung W, Holder A, Martin A, Sweeney E, Mitchell J, Bachman S, Pau CP, Heneine W, Garcia-Lerma JG (2012) Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS ONE 7(12):e50632CrossRefGoogle Scholar
  161. Radzio J, Spreen W, Yueh YL, Mitchell J, Jenkins L, Garcia-Lerma JG, Heneine W (2015) The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge. Sci Transl Med 7(270):270ra275. doi:10.1126/scitranslmed.3010297CrossRefGoogle Scholar
  162. Rajasuriar R, Wright E, Lewin SR (2015) Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damage. Curr Opin HIV AIDS 10(1):35–42. doi:10.1097/coh.0000000000000118CrossRefPubMedPubMedCentralGoogle Scholar
  163. Read PJ, Mandalia S, Khan P, Harrisson U, Naftalin C, Gilleece Y, Anderson J, Hawkins DA, Taylor GP, de Ruiter A, London HIVPRG (2012) When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS 26(9):1095–1103. doi:10.1097/QAD.0b013e3283536a6cCrossRefPubMedGoogle Scholar
  164. Reimann KA, Parker RA, Seaman MS, Beaudry K, Beddall M, Peterson L, Williams KC, Veazey RS, Montefiori DC, Mascola JR, Nabel GJ, Letvin NL (2005) Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol 79(14):8878–8885. doi:10.1128/JVI.79.14.8878-8885.2005CrossRefPubMedPubMedCentralGoogle Scholar
  165. Reynolds MR, Sacha JB, Weiler AM, Borchardt GJ, Glidden CE, Sheppard NC, Norante FA, Castrovinci PA, Harris JJ, Robertson HT, Friedrich TC, McDermott AB, Wilson NA, Allison DB, Koff WC, Johnson WE, Watkins DI (2011) The TRIM5α genotype of rhesus macaques affects acquisition of simian immunodeficiency virus SIVsmE660 infection after repeated limiting-dose intrarectal challenge. J Virol 85(18):9637–9640. doi:10.1128/JVI.05074-11CrossRefPubMedPubMedCentralGoogle Scholar
  166. Rosenbloom KR, Armstrong J, Barber GP, Casper J, Clawson H, Diekhans M, Dreszer TR, Fujita PA, Guruvadoo L, Haeussler M, Harte RA, Heitner S, Hickey G, Hinrichs AS, Hubley R, Karolchik D, Learned K, Lee BT, Li CH, Miga KH, Nguyen N, Paten B, Raney BJ, Smit AF, Speir ML, Zweig AS, Haussler D, Kuhn RM, Kent WJ (2015) The UCSC genome browser database: 2015 update. Nucleic Acids Res 43(Database issue):D670–681. doi:10.1093/nar/gku1177CrossRefGoogle Scholar
  167. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C, Group AVS (2013) Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog 9(3):e1003211. doi:10.1371/journal.ppat.1003211CrossRefGoogle Scholar
  168. Sanders-Beer BE, Spano YY, Golighty D, Lara A, Hebblewaite D, Nieves-Duran L, Rhodes L, Mansfield KG (2011) Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy. AIDS Res Ther 8(1):3CrossRefGoogle Scholar
  169. Sax PE, Zolopa A, Brar I, Elion R, Ortiz R, Post F, Wang H, Callebaut C, Martin H, Fordyce MW, McCallister S (2014) Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 67(1):52–58. doi:10.1097/QAI.0000000000000225CrossRefPubMedGoogle Scholar
  170. Sellier P, Mannioui A, Bourry O, Dereuddre-Bosquet N, Delache B, Brochard P, Calvo J, Prevot S, Roques P (2010) Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. PLoS ONE 5(5):e10570CrossRefGoogle Scholar
  171. Sharp PM, Robertson DL, Hahn BH (1995) Cross-species transmission and recombination of ‘AIDS’ viruses. Philos Trans R Soc Lond B Biol Sci 349(1327):41–47. doi:10.1098/rstb.1995.0089CrossRefPubMedGoogle Scholar
  172. Shedlock DJ, Silvestri G, Weiner DB (2009) Monkeying around with HIV vaccines: using rhesus macaques to define ‘gatekeepers’ for clinical trials. Nat Rev Immunol 9(10):717–728. doi:10.1038/nri2636CrossRefPubMedPubMedCentralGoogle Scholar
  173. Shen A, Zink MC, Mankowski JL, Chadwick K, Margolick JB, Carruth LM, Li M, Clements JE, Siliciano RF (2003) Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 77(8):4938–4949CrossRefGoogle Scholar
  174. Shen A, Yang HC, Zhou Y, Chase AJ, Boyer JD, Zhang H, Margolick JB, Zink MC, Clements JE, Siliciano RF (2007) Novel pathway for induction of latent virus from resting CD4(+) T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol 81(4):1660–1670CrossRefGoogle Scholar
  175. Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, Zhou Y, Pitt E, Anderson KS, Acosta EP, Siliciano RF (2008) Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14(7):762–766. doi:10.1038/nm1777CrossRefPubMedPubMedCentralGoogle Scholar
  176. Sheppard NC, Jones RB, Burwitz BJ, Nimityongskul FA, Newman LP, Buechler MB, Reed JS, Piaskowski SM, Weisgrau KL, Castrovinci PA, Wilson NA, Ostrowski MA, Park B, Nixon DF, Rakasz EG, Sacha JB (2014) Vaccination against endogenous retrotransposable element consensus sequences does not protect rhesus macaques from SIVsmE660 infection and replication. PLoS ONE 9(3):e92012. doi:10.1371/journal.pone.0092012CrossRefPubMedPubMedCentralGoogle Scholar
  177. Shinohara K, Sakai K, Ando S, Ami Y, Yoshino N, Takahashi E, Someya K, Suzaki Y, Nakasone T, Sasaki Y, Kaizu M, Lu Y, Honda M (1999) A highly pathogenic simian/human immunodeficiency virus with genetic changes in cynomolgus monkey. J Gen Virol 80(Pt 5):1231–1240. doi:10.1099/0022-1317-80-5-1231CrossRefPubMedGoogle Scholar
  178. Shytaj IL, Norelli S, Chirullo B, Della Corte A, Collins M, Yalley-Ogunro J, Greenhouse J, Iraci N, Acosta EP, Barreca ML, Lewis MG, Savarino A (2012) A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog 8(6):e1002774CrossRefGoogle Scholar
  179. Silvestri G, Sodora DL, Koup RA, Paiardini M, O’Neil SP, McClure HM, Staprans SI, Feinberg MB (2003) Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 18(3):441–452CrossRefGoogle Scholar
  180. Silvestri G, Fedanov A, Germon S, Kozyr N, Kaiser WJ, Garber DA, McClure H, Feinberg MB, Staprans SI (2005) Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol 79(7):4043–4054. doi:10.1128/JVI.79.7.4043-4054.2005CrossRefPubMedPubMedCentralGoogle Scholar
  181. Simonetti FR, Sobolewski MD, Fyne E, Shao W, Spindler J, Hattori J, Anderson EM, Watters SA, Hill S, Wu X, Wells D, Su L, Luke BT, Halvas EK, Besson G, Penrose KJ, Yang Z, Kwan RW, Van Waes C, Uldrick T, Citrin DE, Kovacs J, Polis MA, Rehm CA, Gorelick R, Piatak M, Keele BF, Kearney MF, Coffin JM, Hughes SH, Mellors JW, Maldarelli F (2016) Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo. Proc Natl Acad Sci USA 113(7):1883–1888. doi:10.1073/pnas.1522675113CrossRefPubMedGoogle Scholar
  182. Snippenburg W, Nellen F, Smit C, Wensing A, Godfried MH, Mudrikova T (2017) Factors associated with time to achieve an undetectable HIV RNA viral load after start of antiretroviral treatment in HIV-1-infected pregnant women. J Virus Erad 3(1):34–39PubMedPubMedCentralGoogle Scholar
  183. Somsouk M, Dunham RM, Cohen M, Albright R, Abdel-Mohsen M, Liegler T, Lifson J, Piatak M, Gorelick R, Huang Y, Wu Y, Hsue PY, Martin JN, Deeks SG, McCune JM, Hunt PW (2014) The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. PLoS ONE 9(12):e116306. doi:10.1371/journal.pone.0116306CrossRefPubMedPubMedCentralGoogle Scholar
  184. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, Grisson RD, Xu W, Whitney JB, Goins LM, Ong H, Li PL, Shai-Kobiler E, Wang T, McCann CM, Zhang H, Wood C, Kankasa C, Secor WE, McClure HM, Strobert E, Else JG, Ruprecht RM (2006) Molecularly cloned SHIV-1157ipd3N4: a highly replication-competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 80(17):8729–8738. doi:10.1128/JVI.00558-06CrossRefPubMedPubMedCentralGoogle Scholar
  185. Steingrover R, Pogany K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, Miedema F, Lange JM, Prins JM (2008) HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Aids 22(13):1583–1588CrossRefGoogle Scholar
  186. Stoddart CA, Galkina SA, Joshi P, Kosikova G, Moreno ME, Rivera JM, Sloan B, Reeve AB, Sarafianos SG, Murphey-Corb M, Parniak MA (2015) Oral administration of the nucleoside EFdA (4′-ethynyl-2-fluoro-2′-deoxyadenosine) provides rapid suppression of HIV viremia in humanized mice and favorable pharmacokinetic properties in mice and the rhesus macaque. Antimicrob Agents Chemother 59(7):4190–4198. doi:10.1128/AAC.05036-14CrossRefPubMedPubMedCentralGoogle Scholar
  187. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J (2004) The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427(6977):848–853. doi:10.1038/nature02343CrossRefPubMedGoogle Scholar
  188. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F, Anderson DJ, Sundquist WI, Sodroski J (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA 103(14):5514–5519. doi:10.1073/pnas.0509996103CrossRefPubMedGoogle Scholar
  189. Sumpter B, Dunham R, Gordon S, Engram J, Hennessy M, Kinter A, Paiardini M, Cervasi B, Klatt N, McClure H, Milush JM, Staprans S, Sodora DL, Silvestri G (2007) Correlates of preserved CD4(+) T cell homeostasis during natural, nonpathogenic simian immunodeficiency virus infection of sooty mangabeys: implications for AIDS pathogenesis. J Immunol 178(3):1680–1691CrossRefGoogle Scholar
  190. Tan RC, Harouse JM, Gettie A, Cheng-Mayer C (1999) In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein. J Med Primatol 28(4–5):164–168CrossRefGoogle Scholar
  191. Tanner Z, Lachowsky N, Ding E, Samji H, Hull M, Cescon A, Patterson S, Chia J, Leslie A, Raboud J, Loutfy M, Cooper C, Klein M, Machouf N, Tsoukas C, Montaner J, Hogg RS, Canadian Observation Cohort C (2016) Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect Dis 16(1):590. doi:10.1186/s12879-016-1926-zCrossRefPubMedPubMedCentralGoogle Scholar
  192. Tartaglia LJ, Chang HW, Lee BC, Abbink P, Ng’ang’a D, Boyd M, Lavine CL, Lim SY, Sanisetty S, Whitney JB, Seaman MS, Rolland M, Tovanabutra S, Ananworanich J, Robb ML, Kim JH, Michael NL, Barouch DH (2016) Production of mucosally transmissible SHIV challenge stocks from HIV-1 circulating recombinant form 01_AE env sequences. PLoS Pathog 12(2):e1005431. doi:10.1371/journal.ppat.1005431CrossRefPubMedPubMedCentralGoogle Scholar
  193. Thippeshappa R, Polacino P, Yu Kimata MT, Siwak EB, Anderson D, Wang W, Sherwood L, Arora R, Wen M, Zhou P, Hu SL, Kimata JT (2011) Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1. J Virol 85(8):3767–3779CrossRefGoogle Scholar
  194. Trichel AM, Rajakumar PA, Murphey-Corb M (2002) Species-specific variation in SIV disease progression between Chinese and Indian subspecies of rhesus macaque. J Med Primatol 31(4–5):171–178CrossRefGoogle Scholar
  195. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, Benveniste RE, Black R (1995) Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 270(5239):1197–1199CrossRefGoogle Scholar
  196. Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, Lifson JD, Morton WR (1998) Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 72(5):4265–4273PubMedPubMedCentralGoogle Scholar
  197. Tsibris AM, Pal U, Schure AL, Veazey RS, Kunstman KJ, Henrich TJ, Klasse PJ, Wolinsky SM, Kuritzkes DR, Moore JP (2011) SHIV-162P3 infection of rhesus macaques given maraviroc gel vaginally does not involve resistant viruses. PLoS ONE 6(12):e28047. doi:10.1371/journal.pone.0028047CrossRefPubMedPubMedCentralGoogle Scholar
  198. Uberla K, Stahl-Hennig C, Bottiger D, Matz-Rensing K, Kaup FJ, Li J, Haseltine WA, Fleckenstein B, Hunsmann G, Oberg B et al (1995) Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci USA 92(18):8210–8214CrossRefGoogle Scholar
  199. Vaccari M, Boasso A, Fenizia C, Fuchs D, Hryniewicz A, Morgan T, Weiss D, Doster MN, Heraud JM, Shearer GM, Franchini G (2012) Fatal pancreatitis in simian immunodeficiency virus SIV(mac251)-infected macaques treated with 2’,3’-dideoxyinosine and stavudine following cytotoxic-T-lymphocyte-associated antigen 4 and indoleamine 2,3-dioxygenase blockade. J Virol 86(1):108–113CrossRefGoogle Scholar
  200. Vagenas P, Aravantinou M, Williams VG, Jasny E, Piatak M Jr, Lifson JD, Salazar AM, Blanchard JL, Gettie A, Robbiani M (2010) A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation. PLoS ONE 5(9):e12891. doi:10.1371/journal.pone.0012891CrossRefPubMedPubMedCentralGoogle Scholar
  201. Van Rompay KK, Matthews TB, Higgins J, Canfield DR, Tarara RP, Wainberg MA, Schinazi RF, Pedersen NC, North TW (2002) Virulence and reduced fitness of simian immunodeficiency virus with the M184 V mutation in reverse transcriptase. J Virol 76(12):6083–6092CrossRefGoogle Scholar
  202. Van Rompay KK, Durand-Gasselin L, Brignolo LL, Ray AS, Abel K, Cihlar T, Spinner A, Jerome C, Moore J, Kearney BP, Marthas ML, Reiser H, Bischofberger N (2008) Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 52(9):3144–3160CrossRefGoogle Scholar
  203. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, Knight HL, Rosenzweig M, Johnson RP, Desrosiers RC, Lackner AA (1998) Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280(5362):427–431CrossRefGoogle Scholar
  204. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, Marx PA, Dufour J, Colonno RJ, Shattock RJ, Springer MS, Moore JP (2005a) Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 438(7064):99–102. doi:10.1038/nature04055CrossRefGoogle Scholar
  205. Veazey RS, Springer MS, Marx PA, Dufour J, Klasse PJ, Moore JP (2005b) Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med 11(12):1293–1294. doi:10.1038/nm1321CrossRefPubMedGoogle Scholar
  206. Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP (2010) Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 202(5):739–744. doi:10.1086/655661CrossRefPubMedPubMedCentralGoogle Scholar
  207. Vinikoor MJ, Cope A, Gay CL, Ferrari G, McGee KS, Kuruc JD, Lennox JL, Margolis DM, Hicks CB, Eron JJ (2013) Antiretroviral therapy initiated during acute HIV infection fails to prevent persistent T-cell activation. J Acquir Immune Defic Syndr 62(5):505–508. doi:10.1097/QAI.0b013e318285cd33CrossRefPubMedPubMedCentralGoogle Scholar
  208. Virgen CA, Kratovac Z, Bieniasz PD, Hatziioannou T (2008) Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc Natl Acad Sci USA 105(9):3563–3568. doi:10.1073/pnas.0709258105CrossRefPubMedGoogle Scholar
  209. von Wyl V, Gianella S, Fischer M, Niederoest B, Kuster H, Battegay M, Bernasconi E, Cavassini M, Rauch A, Hirschel B, Vernazza P, Weber R, Joos B, Gunthard HF (2011) Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS ONE 6(11):e27463CrossRefGoogle Scholar
  210. Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, Huang HC, Edlefsen PT, Mullins JI, Frenkel LM (2014) HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345(6196):570–573. doi:10.1126/science.1256304CrossRefGoogle Scholar
  211. Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y (2012) RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14(1):22–29CrossRefGoogle Scholar
  212. Whetter LE, Ojukwu IC, Novembre FJ, Dewhurst S (1999) Pathogenesis of simian immunodeficiency virus infection. J Gen Virol 80(Pt 7):1557–1568CrossRefGoogle Scholar
  213. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J, Blackmore S, Smith JY, Brinkman AL, Peter LE, Mathew SI, Smith KM, Borducchi EN, Rosenbloom DI, Lewis MG, Hattersley J, Li B, Hesselgesser J, Geleziunas R, Robb ML, Kim JH, Michael NL, Barouch DH (2014) Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature 512(7512):74–77. doi:10.1038/nature13594CrossRefPubMedPubMedCentralGoogle Scholar
  214. Yeh WW, Rao SS, Lim SY, Zhang J, Hraber PT, Brassard LM, Luedemann C, Todd JP, Dodson A, Shen L, Buzby AP, Whitney JB, Korber BT, Nabel GJ, Mascola JR, Letvin NL (2011) The TRIM5 gene modulates penile mucosal acquisition of simian immunodeficiency virus in rhesus monkeys. J Virol 85(19):10389–10398. doi:10.1128/JVI.00854-11CrossRefPubMedPubMedCentralGoogle Scholar
  215. Zeldin RK, Petruschke RA (2004) Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 53(1):4–9. doi:10.1093/jac/dkh029CrossRefPubMedGoogle Scholar
  216. Zink MC, Suryanarayana K, Mankowski JL, Shen A, Piatak M Jr, Spelman JP, Carter DL, Adams RJ, Lifson JD, Clements JE (1999) High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 73(12):10480–10488PubMedPubMedCentralGoogle Scholar
  217. Zink MC, Brice AK, Kelly KM, Queen SE, Gama L, Li M, Adams RJ, Bartizal C, Varrone J, Rabi SA, Graham DR, Tarwater PM, Mankowski JL, Clements JE (2010) Simian immunodeficiency virus-infected macaques treated with highly active antiretroviral therapy have reduced central nervous system viral replication and inflammation but persistence of viral DNA. J Infect Dis 202(1):161–170CrossRefGoogle Scholar
  218. Zuber B, Bottiger D, Benthin R, ten Haaft P, Heeney J, Wahren B, Oberg B (2001) An in vivo model for HIV resistance development. AIDS Res Hum Retroviruses 17(7):631–635CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.AIDS and Cancer Virus ProgramFrederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc.FrederickUSA

Personalised recommendations